Utility of an immune cell function assay to differentiate rejection from infectious enteritis in pediatric intestinal transplant recipients

Clinical Transplantation

Volumn 28, Issue 2, 2014, Pages 229-235

  Wozniak, Laura J ^a   Venick, Robert S ^a   Gordon Burroughs, Sherilyn ^b   Ngo, Khiet D ^c   Duffy, John P ^d   Farmer, Douglas G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

Author keywords

CD4+ T cell; Cylex ImmuKnow assay; Infection; Intestinal transplantation; Rejection

Indexed keywords

CD4+  T CELL; CYLEX IMMUKNOW ASSAY; INFECTION; INTESTINAL TRANSPLANTATION; REJECTION;

ADENOSINE TRIPHOSPHATE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; DIAGNOSIS, DIFFERENTIAL; ENTERITIS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOASSAY; INTESTINES; JEJUNAL DISEASES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84895073859     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12303     Document Type: Article

References (27)

1. Mazariegos GV, Steffick DE, Horslen S et al. Intestine transplantation in the United States, 1999-2008. Am J Transplant 2010: 10(4 Pt 2): 1020.
2. David AI, Selvaggi G, Ruiz P et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation 2007: 84: 1077.
3. Ruiz P, Tryphonopoulos P, Island E et al. Citrulline evaluation in bowel transplantation. Transplant Proc 2010: 42: 54.
4. Akpinar E, Vargas J, Kato T et al. Fecal calprotectin level measurements in small bowel allograft monitoring: a pilot study. Transplantation 2008: 85: 1281.
5. Cagnola H, Scaravonati R, Cabanne A et al. Evaluation of calprotectin level in intestinal content as an early marker for graft rejection. Transplant Proc 2010: 42: 57.
6. Mercer DF, Vargas L, Sun Y et al. Stool calprotectin monitoring after small intestine transplantation. Transplantation 2011: 91: 1166.
7. Sudan D, Vargas L, Sun Y, Bok L, Dijkstra G, Langnas A. Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007: 246: 311.
8. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003: 17: 77.
9. Hooper E, Hawkins DM, Kowalski RJ et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 2005: 19: 834.
10. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006: 82: 663.
11. Israeli M, Ben-Gal T, Yaari V et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 2010: 89: 968.
12. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011: 6: 423.
13. Millan O, Sanchez-Fueyo A, Rimola A et al. Is the intracellular ATP concentration of CD4 + T-Cells a predictive biomarker of immune status in stable transplant recipients? Transplantation 2009: 88(3 Suppl): S78.
14. Serban G, Whittaker V, Fan J et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. Hum Immunol 2009: 70: 882.
15. Xue F, Zhang J, Han L et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 2010: 89: 620.
16. Cabrera R, Ararat M, Soldevila-Pico C et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009: 15: 216.
17. Hashimoto K, Miller C, Hirose K et al. Measurement of CD4 + T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010: 24: 701.
18. Zeevi A, Britz JA, Bentlejewski CA et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005: 15: 17.
19. Farmer DG, Venick RS, Colangelo J et al. Pretransplant predictors of survival after intestinal transplantation: analysis of a single-center experience of more than 100 transplants. Transplantation 2010: 90: 1574.
20. Ruiz P, Bagni A, Brown R et al. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc 2004: 36: 335.
21. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000: 21: 192.
22. Israeli M, Klein T, Sredni B et al. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 2008: 14: 893.
23. Schulz-Juergensen S, Burdelski MM, Oellerich M, Brandhorst G. Intracellular ATP production in CD4 + T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy. Ther Drug Monit 2012: 34: 4.
24. Ling X, Xiong J, Liang W et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012: 93: 737.
25. Uemura T, Riley TR, Khan A et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant 2011: 25: E32.
26. Elidemir O, Kancherla BS, Schecter MG et al. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring. Pediatr Transplant 2009: 13: 606.
27. Gautam A, Morrissey PE, Brem AS et al. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant 2006: 10: 613.